fbpx

Tyvaso (treprostinil) Drug Overview & Product Profile 2019 – ResearchAndMarkets.com

26 Views

DUBLIN–(BUSINESS WIRE)–The “Tyvaso” report has been added to ResearchAndMarkets.com’s offering.

United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil, Tyvaso is better tolerated than continuously and subcutaneously administered Remodulin.

Analyst Outlook

United Therapeutics has created a large market niche for its inhaled treprostinil formulation, Tyvaso, despite the drug being relegated to later lines of therapy and being unavailable outside the US. However, this niche is now under threat from newer, more convenient oral prostacyclins such as Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku), which further possesses a much stronger clinical dataset, as well as United Therapeutics’ own oral Orenitram (treprostinil).

While these products have carved out a portion of Tyvaso’s market share, United Therapeutics may yet recoup losses through a first-to-market label expansion in pulmonary hypertension associated with lung disease (PH-LD). This will revive Tyvaso’s sales growth and dampen potential competition from LIQ861 (treprostinil; Liquidia Technologies) – a dry powder for inhalation currently in Phase III.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Tyvaso: Pulmonary hypertension

LIST OF FIGURES

Figure 1: Tyvaso for pulmonary hypertension – SWOT analysis

Figure 2: The authors drug assessment summary of Tyvaso for pulmonary hypertension

Figure 3: Tyvaso sales for pulmonary hypertension in the US, 2016-25

LIST OF TABLES

Table 1: Tyvaso drug profile

Table 2: Tyvaso pivotal trial data in pulmonary hypertension

Table 3: Tyvaso ongoing late-phase trials in pulmonary hypertension

Table 4: Tyvaso sales for pulmonary hypertension in the US ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/t3e6b3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Cardiovascular Drugs

leverton

I have been involved with publishing and marketing for the past 37 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.For people who love to save money and earn while saving, there is a new program called the r network. You are provided with a card that entitles the user to automatic savings on more than 300,000 products. Learn more about the revv card today. This is by invitation only to be some of the first people to get this card.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.

You May Also Like